Study to compare Centchroman vs. Tamoxifen for the management of breast pain

CENTCHROMAN VS TAMOXIFEN FOR REGRESSION OF MASTALGIA: A DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/05/002658

Enrollment

Registered

2012-05-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- mastalgia

Interventions

Intervention1: Centchroman: Centchroman 30 mg daily orally for 3 months Control Intervention1: Tamoxifen: Tamoxifen 10 mg orally daily for three months

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients having mastalgia with VAS score above 3/10 2. Duration of mastalgia > 3 months

Exclusion criteria

Exclusion criteria: 1. Past history of breast carcinoma or family history of breast carcinoma. 2. Acute inflammatory breast conditions 3. Discrete breast lumps 4. Patients with oligomenorrhoea, irregular bleeding, ovarian cysts or cervical hyperplasia. 5. Lactation period â?? first 6 months 6. Pregnant or planning to conceive

Design outcomes

Primary

Measure	Time frame
Pain relief to VAS score 3/10 or lessTimepoint: 4 weeks 8 weeks 12 weeks 24 weeks	—

Secondary

Measure	Time frame
1. Improvement in quality of life 2. Side effects Timepoint: 24 weeks	—

Countries

India

Contacts

Public ContactAmit Bansal

University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi

bhupendrakjain@gmail.com01122692536

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026